Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection

Biochemical Pharmacology

Volumn 53, Issue 6, 1997, Pages 755-763

  Baier Bitterlich, Gabriele ^a   Fuchs, Dietmar ^a   Wachter, Helmut ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

7,8 dihydroneopterin; AIDS; apoptosis; human immunodeficiency virus; neopterin; oxidative stress

Indexed keywords

7,8 DIHYDRONEOPTERIN; CD4 ANTIGEN; GAMMA INTERFERON; NEOPTERIN; UNCLASSIFIED DRUG;

APOPTOSIS; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0030944017     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00651-X     Document Type: Note

References (123)

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W and Montagnier L, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871, 1983.
2. Popovic M, Sarngadharan MG, Read E and Gallo RC, Detection, isolation and continuous production of cytopathic retroviruses (HTLV III) from patients with AIDS and preAIDS. Science 224: 497-500, 1984.
3. Fuchs D and Wachter H, Neopterin-ein Marker für den zellulären Immunstatus-Bedeutung bei AIDS, ARC und AIDS-Risikogruppen. In: AlDS-Acquired Immune Deficiency Syndrome - Symposium Wien 1985 (Eds. Gschnait F and Wolff K), pp. 96-127. Springer, Wien, 1985.
4. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS and Gallo RC, Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS. Science 231: 850-853, 1986.
5. Fauci AS, Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 262: 1011-1018, 1993.
6. Gougeon ML and Montagnier L, Apoptosis in AIDS. Science 260: 1269-1270, 1993.
7. Nathan CF, Secretory products of macrophages. J Clin Invest 79: 319-326, 1987.
8. Billiau A and Dijkmans R, Interferon-γ: Mechanisms of action and therapeutic potential. Biochem Pharmacol 40: 1433-1439, 1990.
9. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J and Wachter H, Immune response-associated production of neopterin. J Exp Med 160: 310-316, 1984.
10. Bitterlich G, Szabo G, Werner ER, Larcher C, Fuchs D, Hausen A, Reibnegger G, Schulz TF, Troppmair J and Wachter H, Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 176: 228-235, 1988.
11. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner E and Werner-Felmayer, Neopterin. Walter de Gruyter, Berlin, 1992.
12. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP and Wachter H, Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today 9: 150-155, 1988.
13. Wachter H, Hausen A and Grassmayr K, Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Hoppe-Seyler's Z Physiol Chem 360: 1957-1960, 1979.
14. Wachter H, Fuchs D, Hausen A, Reibnegger G and Werner ER, Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 27: 81-141, 1989.
15. Fuchs D, Milstien S, Krämer A, Reibnegger G, Werner ER, Goedert JJ, Kaufman S and Wachter H, Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 35: 2305-2307, 1989.
16. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP and Wachter H, Neopterin modulates toxicity by reactive oxygen and chloride species. FEBS Lett 321: 89-92, 1993.
17. Murr C, Fuchs D, Gössler W, Hausen A, Reibnegger G, Werner ER and Werner-Felmayer G, Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 338: 223-226, 1994.
18. Reibnegger G, Fuchs D, Murr C, Dierich MP, Pfleiderer W and Wachter H, Effects of pteridines on luminol-dependent chemiluminescence induced by chloramine-T. Free Radic Biol Med 18: 515-523, 1995.
19. Fuchs D, Gruber A, Überall F and Wachter H, Oxidative stress and apoptosis. Immunol Today 15: 496, 1994.
20. Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R, Böck G, Dierich MP and Wachter H, Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-α induced programmed cell death. FEBS Lett 364: 234-238, 1995.
21. Baier-Bitterlich G, Fuchs D, Zangerle R, Baeuere PA, Werner ER, Fresser F, Überall F, Baier G and Wachter H, Transactivation of the HIV-1 promoter by 7,8-dihydroneopterin in vitro. AIDS Res Human Retrovir, in press.
22. Hoffmann G, Schobersberger W, Frede S, Peizer L, Fandrey J, Wachter H, Fuchs D and Grote J, Neopterin induces translocation of nuclear factor κB to the nucleus of vascular smooth muscle cells. FEBS Lett, in press.
23. Schreck R, Rieber P and Baeuerle PA, Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 10: 2247-2258, 1991.
24. Greenspan HC and Aruoma OI, Oxidative stress and apoptosis in HIV infection: A role for plant-derived metabolites with synergistic antioxidant activity. Immunol Today 15: 209-213, 1994.
25. Dröge W, Eck H-P and Mihm S, HIV-induced cysteine deficiency and T-cell dysfunction - A rationale for treatment with N-acetylcysteine. Immunol Today 13: 211-213, 1992.
26. Buttke TM and Sandstrom PA, Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10, 1994.
27. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P and Markham PD, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500-503, 1984.
28. Evans LA and Levy JA, The heterogeneity and pathogenicity of HIV. In: HIV Molecular Organization, Pathogenicity and Treatment (Eds. Morrow WJW and Haigwood NL), pp. 29-73. Elsevier, Amsterdam; 1993.
29. Pantaleo G, Graziosi C and Fauci AS, Mechanisms of disease: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335, 1993.
30. Levy JA, Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57: 183-289, 1993.
31. Daar ES, Moudgil T, Meyer RD and Ho DD, Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engi J Med 324: 961-964, 1991.
32. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PS, Kappes JL, Hahn BH and Shaw GM, High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 324: 954-960, 1991.
33. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS and Shaw GM, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122, 1995.
34. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126, 1995.
35. Coffin JM, HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489, 1995.
36. Fauci AS, The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 239: 617-622, 1988.
37. Rosenberg ZF and Fauci AS, The immunopathogenesis of HIV infection. Adv Immunol 47: 377-431, 1989.
38. Coffman RL, Varkila K, Scott P and Chatelain R, Role of cytokines in the differentiation of CD4 T-cell subsets in vivo. Immunol Rev 123: 189-207, 1991.
39. Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TAT, Bond MW, Moore KWM, Sher A and Fiorentino DF, Diversity of cytokine synthesis and function of mouse CD4 T cells. Immunol Rev 123: 209-229, 1991.
40. Powrie F and Coffman RL, Cytokine regulation of T cell function: Potential for therapeutic intervention. Immunol Today 14: 270-274, 1993.
41. Romagnani S, Human TH1 and TH2 subsets: Doubt no more. Immunol Today 12: 256-257, 1991.
42. Romagnani S, Induction of TH1 and TH2 responses: A key role for the 'natural' immune response? Immunol Today 13: 379-381, 1992.
43. Clerici M, Lucey P, Berzofsky J, Pinto L, Wynn T, Blatt S, Dolan M, Hendrix C, Wolf S and Shearer G, Restoration of HIV-specific cell-mediated immune response by IL-12 in vitro. Science 262: 1721-1724, 1993.
44. H2 switch is a critical step in the etiology of HIV infection. Immunol Today 14: 107-111, 1993.
45. Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Dierich MP and Wachter H, Interferon-γ concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 2: 158-162, 1989.
46. Emilie D, Peuchmaur M, Maillot MC, Crevon MC, Brousse N, Delfraissy JF, Dormont J and Galanaud P, Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 86: 148-159, 1990.
47. Ameisen JC, Estaquier J and Idziorek T, From AIDS to parasite infection: Pathogen-mediated subversion of programmed cell death as a mechanism for immune dysregulation. Immunol Rev 142: 9-51, 1994.
48. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly R and Fauci AS, Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265: 248-252, 1994.
49. Fan J, Bass HZ and Fahey JL, Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J Immunol 151: 5031-5040, 1993.
50. Heagy W, Groopman J, Schindler J and Finberg R, Use of interferon-γ in patients with AIDS. J Acquir Immun Defic Syndr 3: 584-590, 1990.
51. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G and Wachter H, Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 23: 103-108, 1989.
52. Fuchs D, Zangerle R, Artner-Dworzak E, Weiss G, Fritsch P, Tilz GP, Dierich MP and Wachter H, Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection. Eur J Haematol 50: 90-94, 1993.
53. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reib-negger G, and Wachter H, Parallel induction of tetrahydro-biopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-γ. Biochem J 262: 861-866, 1989.
54. Denz H, Fuchs D, Hausen A, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER and Wachter H, Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin Wochenschr 68: 218-222, 1990.
55. Weiss G, Glaser K, Kronberger P, Ambach E, Fuchs D, Bodner E and Wachter H, Distinct distributions of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation. Biol Chem Hoppe Seyler 373: 289-294, 1992.
56. Levine RA and Milstien S, The ratio of reduced to oxidized neopterin and biopterin in human fluids: Significance to the study of human disease. In: Biochemical and Clinical Aspects of Pteridines (Eds. Pfleiderer W, Wachter H and Curtius H-C), Vol. 3, pp. 277-284. Walter de Gruyter, Berlin, 1984.
57. Fuchs D, Werner ER and Wachter H, Soluble products of immune activation: Neopterin. In: Manual of Clinical Laboratory Immunology (Eds. Rose NR, deMacario EC, Fahey JL, Friedman H and Penn GM), pp. 251-255. American Society for Microbiology, Washington, DC, 1992.
58. Fuchs D, Stahl-Hennig C, Gruber A, Murr C, Hunsmann G and Wachter H, Neopterin - Its clinical use in urinanalysis. Kidney Int 46: 8-11, 1994.
59. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K, Weiss G and Wachter H, Pteridine biosynthesis in human endothelial cells. J Biol Chem 268: 1842-1846, 1993.
60. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, Pfleiderer W and Wachter H, Tetrahy-drobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T24 cells. J Biol Chem 265: 3189-3192, 1990.
61. Fuchs D, Hausen A, Reibnegger G, Reissigl H, Schönitzer D, Spira T and Wachter H, Urinary neopterin in the diagnosis of acquired immune deficiency syndrome. Eur J Clin Microbiol 3: 70-71, 1984.
62. Fuchs D, Hausen A, Huber C, Margreiter R, Reibnegger G, Spielberger M and Wachter H, Pteridinausscheidung als Marker für alloantigen-induzierte Lymphozytenproliferation. Hoppe-Seyler's Z Physiol Chem 363: 661-664, 1982.
63. Fuchs D, Jäger H, Popescu M, Reibnegger G, Werner ER, Dierich MP, Kaboth W, Tilz GP and Wachter H, Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 26: 75-79, 1990.
64. Baier-Bitterlich G, Wachter H and Fuchs D, The role of neopterin and 7,8-dihydroneopterin in human immunodeficiency virus infection: Marker for disease progression and pathogenic link. J Acquir Immune Defic Syndr, in press.
65. Ameisen JC and Capron A, Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today 12: 102-105, 1991.
66. Wyllie AH, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555-556, 1980.
67. Duvall E and Wyllie AH, Death and the cell. Immunol Today 7: 115-119, 1986.
68. Arends MJ and Wyllie AH, Apoptosis. Mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254, 1991.
69. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RPM and Miedema F, Programmed death of T cells in HIV-1 infection. Science 257: 217-219, 1992.
70. Gougeon ML, Colizzi V, Dalgleish A and Montagnier L, New concepts in AIDS pathogenesis. AIDS Res Hum Retroviruses 9: 287-289, 1993.
71. + T cells from HIV-infected persons. J Immunol 153: 412-420, 1994.
72. Muro-Cacho CA, Pantaleo G and Fauci AS, Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 154: 5555-5566, 1995.
73. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly R-P and Finkel TH, Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 176: 1099-1106, 1992.
74. Cohen DI, Tani Y, Tian H, Boone E, Samelson L and Lane HC, Participation of tyrosine phosphorylation in the cytopathic effect of HIV-1. Science 256: 542-545, 1992.
75. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS and Pahwa S, Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 82: 3392-3400, 1993.
76. Laurent-Crawford AG, Krust B, Muller S, Riviere Y, Rey-Cuille MA, Bechet JM, Montagnier L and Hovanessian AG, The cytopathic effect of HIV is associated with apoptosis. Virology 185: 829-839, 1991.
77. Tian H, Kolesnitchenko V, Donoghue E, Shaw G, Lane C and Cohen D, HIV envelope-directed CD4 T-cell degeneration represents a novel cell death program. In: The First National Conference on Human Retroviruses and Related Infections, Abstr. 275. American Society for Microbiology, Washington, DC, 1993.
78. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM and Kupfer A, Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nature Med 1: 129-134, 1995.
79. Ledbetter JA, June CH, Rabinovitch PS, Grossmann A, Tsu TT and Imboden JB, Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur J Immunol 18: 525-532, 1988.
80. Mittler RS and Huffman MK, Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Science 245: 1380-1382, 1989.
81. Linette GP, Hartzman RJ, Ledbetter JA and June C, HIV-1 infected T-cells show a selective signaling defect after perturbation of CD3/antigen receptor. Science 241: 573-576, 1988.
82. Hofmann B, Nishanian P, Baldwin RL, Insixiengmay P, Nel A and Fahey JL, HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism. J Immunol 145: 3699-3705, 1990.
83. lck in CD4-mediated suppression of CD3-induced early signaling events in T lymphocytes. Life Sci 56: 1287-1297, 1995.
84. Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A and Krammer P, High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood 83: 3101-3103, 1994.
85. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA and Herzenberg LA, Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 181: 2029-2036, 1995.
86. + T cells from HIV-infected patients increases with disease progression. J Mol Med 73: 591-593, 1995.
87. Nagata S and Golstein P, The Fas death factor. Science 267: 1449-1456, 1995.
88. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS and Pahwa S, Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood 84: 2622-2631, 1994.
89. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnik R, Altman A and Green D, Fas-induced apoptosis is mediated via a ceramide-initiated Ras signaling pathway. Immunity 2: 341-351, 1995.
90. Cullen BR, Does HIV-1 Tat induce a change in viral initiation rights? Cell 73: 417-420, 1993.
91. Westendorp MO, Li-Weber M, Frank RW and Krammer PH, Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 68: 4177-4185, 1994.
92. Viscidi RP, Mayur K, Lederman HM and Frankel AD, Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246: 1606-1608, 1989.
93. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, Dragonetti E, Quinto I and Venuta S, The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 Tat protein. J Exp Med 179: 961-971, 1994.
94. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Dröge W and Lehmann V, HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J 14: 546-554, 1995.
95. Li CJ, Friedman DJ, Wang C, Metelev V and Pardee AB, Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268: 429-431, 1995.
96. Pantaleo G and Fauci AS, Tracking HIV during disease progression. Curr Opin Immunol 6: 600-604, 1994.
97. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoisier M, Goujard C, Debord T and Montagnier L, Programmed cell death in peripheral lymphocytes from HIV-infected persons. J Immunol 156: 3509-3520, 1996.
98. Fuchs D, Reibnegger G, Werner-Felmayer G, Dierich MP and Wachter H, IFN-γ to treat patients wit AIDS. J Acquir Immune Defic Syndr 4: 297-303, 1991.
99. Larrick JW and Wright SC, Cytotoxic mechanisms of tumor necrosis factor-α. FASEB J 4: 3215-3223, 1990.
100. Wright SC, Kumar P, Tam AW, Shen N, Varma M and Larrick JW, Apoptosis and DNA fragmentation precede TNF-induced cytolysis in U937 cells. J Cell Biochem 48: 344-355, 1992.
101. Higuchi M and Aggarwal BB, Differential roles of two types of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation, and differentiation. J Immunol 152: 4017-4025, 1994.
102. Sgonc R and Wick G, Methods for the detection of apoptosis. Int Arch Allergy Immunol 105: 327-332, 1994.
103. Flores SC, Marecki JC, Harper KP, Bose SK, Nelson SK and McCord JM, Tat protein of human immunodeficiency virus type 1 represses expression of manganese Superoxide dismutase in HeLa cells. Proc Natl Acad Sci USA 90: 7632-7636, 1993.
104. Sandstrom PA and Buttke TM, Autocrine production of extracellular catalase prevents apoptosis of the human T-cell line in serum-free medium. Proc Natl Acad Sci USA 90: 4708-4712, 1993.
105. Dröge W, Eck HP, Betzler M, Schlag P, Drings P and Ebert W, Plasma glutamate concentration and lymphocyte activity. J Cancer Res Clin Oncol 114: 124-128, 1988.
106. Eck HP, Gmünder H, Hartmann M, Petzold D, Daniel V and Dröge W, Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-l-infected patients. Biol Chem Hoppe Seyler 370: 101-108, 1989.
107. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, Cantin AM and Crystal RG, Systemic glutathione deficiency in symptom-free HIV seropositive individuals. Lancet ii: 1294-1298, 1989.
108. Roederer M, Staal FJT and Osada H, CD4 and CD8 cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol 3: 933-937, 1991.
109. Eck HP, Mertens T, Rasokat H, Fatkenheuer G, Pohl C, Schrappe M, Daniel V, Naher H, Petzold D, Drings P and Dröge W, T4+ cell numbers are correlated with plasma glutamate and cystine levels: Association of hyperglutamataemia with immunodeficiency in diseases with different aetiologies. Int Immunol 4: 7-13, 1992.
110. Nathan CF, Peroxide and pteridine: A hypothesis on the regulation of macrophage antimicrobial activity by interferon-γ. In: Interferon 7 (Eds. Gresser I and Vicek I), pp. 125-143. Academic Press, 1986.
111. 2-induced luminol chemiluminescence: Mechanistic effects. Free Radic Biol Med, in press.
112. Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LA and Herzenberg LA, Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 87: 4884-4888, 1990.
113. Baeuerle PA and Baltimore D, In: Molecular Aspects of Cellular Regulation. The hormonal Control of Gene Transcription (Eds. Cohen P and Foulkes JG), pp. 409-432. Elsevier/ North Holland Biomedical Press, Amsterdam; 1991
114. Baeuerle PA, The inducible transcription activator NF-κB: Regulation by distinct protein subunits. Biochim Biophys Acta 1072: 63-80, 1991.
115. Greene W, Regulation of HIV-1 gene expression. Annu Rev Immunol 8: 453-475, 1990.
116. Baier-Bitterlich G, Wachter H and Fuchs D, Oxidative stress and apoptosis in HIV infection. Science 271: 582-583, 1996.
117. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 12: 2005-2015, 1993.
118. Devary Y, Gottlieb RA, Lau LF and Karin M, Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol Cell Biol 11: 2804-2811, 1991.
119. Überall F, Werner-Felmayer G, Schubert C, Grunicke HH, Wachter H and Fuchs D, Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett 352: 11-14, 1994.
120. Hannibal MC, Markovitz DM and Nabel GJ, Multiple cisacting elements in the human immunodeficiency virus type 2 enhancer mediate the response to T-cell receptor stimulation by antigen in a T-cell hybridoma line. Blood 83: 1839-1846, 1994.
121. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P and Giorgi JV, The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322: 166-172, 1990.
122. Zangerle R, Gallati H, Sarcletti M, Weiss G, Denz H, Wachter H and Fuchs D, Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 7: 79-85, 1994.
123. Baier-Bitterlich G, Fuchs D and Wachter H, 7,8-Dihydro-neopterin upregulates interferon-γ promoter in T-cells. Immunobiology, in press.